CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:

) ("CEL SCI" or the "Company") today announced that in the month of September it has enrolled 30 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment is now 570 as of September 30, 2015 in the world's largest Phase 3 study in head and neck cancer. A total of 880 patients are expected to be enrolled in over 20 countries.